Key Highlights:
- Orchid Pharma laid the foundation stone for a ₹600 Cr 7-ACA fermentation facility in Jammu & Kashmir, in the presence of Jitendra Singh, marking a key step toward India’s self-reliance in antibiotic raw materials.
- The plant will produce 7-Amino Cephalosporanic Acid (7-ACA), a critical key starting material (KSM) for cephalosporin antibiotics, reducing India’s import dependency. Notably, it will be the first domestic biotech fermentation-based facility for this molecule, aligned with PLI and Make in India initiatives.
- The project also reinforces efforts against antimicrobial resistance (AMR), a major global threat, while highlighting Orchid’s innovation in new antibiotic development. Alongside infrastructure expansion, the company announced treatment access initiatives and collaborations to strengthen India’s biotech ecosystem and manufacturing capabilities.
Implications:
The 7-ACA facility directly strengthens India’s antibiotic supply chain by localizing production of a critical cephalosporin KSM, reducing exposure to import disruptions and price volatility.
Because it is fermentation-based and aligned with PLI and Biopharma Shakti, the project also helps upgrade India’s biomanufacturing capabilities, encouraging more domestic investment in complex biotech intermediates rather than simple, chemical-route APIs.
Coupled with Orchid’s NCE antibiotic and AMR-focused initiatives, the plant positions the company, and the Kathua cluster, as a strategic hub in India’s broader antimicrobial resistance and biopharma agenda, which could attract further partnerships with hospitals, academia, and global pharma.
Source: Express Pharma | Image: Orchid Biopharma
No Comment! Be the first one.